"Top Nasdaq Stocks Poised for Rapid Growth in the Coming Week"

BridgeBio Pharma and Roivant Sciences are two biotech companies with upcoming catalysts that could significantly boost their share prices. BridgeBio is set to announce top-line results from a phase 3 clinical study for its drug acoramidis, targeting a rare heart condition. Positive results could lead to a potential blockbuster drug and acquisition interest. Roivant Sciences may be acquired by Roche for its experimental inflammatory bowel disease drug, RVT-3101, in a rumored $7 billion deal. The potential windfall would greatly benefit Roivant's undervalued stock.